Jeffrey Vacirca

1.0k total citations
31 papers, 744 citations indexed

About

Jeffrey Vacirca is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jeffrey Vacirca has authored 31 papers receiving a total of 744 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Jeffrey Vacirca's work include Cancer Immunotherapy and Biomarkers (10 papers), Prostate Cancer Treatment and Research (6 papers) and Nausea and vomiting management (5 papers). Jeffrey Vacirca is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Prostate Cancer Treatment and Research (6 papers) and Nausea and vomiting management (5 papers). Jeffrey Vacirca collaborates with scholars based in United States, United Kingdom and Spain. Jeffrey Vacirca's co-authors include Stanley Zucker, Péter Ács, Imad A. Tabbara, Peter J. Rosen, Peter P. Lee, Tanios Bekaii‐Saab, Vincent A. Miller, Samuel J. Klempner, Siraj M. Ali and Xiucai Hu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jeffrey Vacirca

28 papers receiving 723 citations

Peers

Jeffrey Vacirca
Chun‐Chieh Wu Taiwan
Philipp Manegold United States
Tingting Zhao China
Véronique Neaud France
Berno Tanner Germany
Yifu He China
Nigel C. Bird United Kingdom
Carolina Bizama Chile
Hye Kyung Hong South Korea
Chun‐Chieh Wu Taiwan
Jeffrey Vacirca
Citations per year, relative to Jeffrey Vacirca Jeffrey Vacirca (= 1×) peers Chun‐Chieh Wu

Countries citing papers authored by Jeffrey Vacirca

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Vacirca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Vacirca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Vacirca more than expected).

Fields of papers citing papers by Jeffrey Vacirca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Vacirca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Vacirca. The network helps show where Jeffrey Vacirca may publish in the future.

Co-authorship network of co-authors of Jeffrey Vacirca

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Vacirca. A scholar is included among the top collaborators of Jeffrey Vacirca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Vacirca. Jeffrey Vacirca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vacirca, Jeffrey, et al.. (2019). Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer. Journal of Infusion Nursing. 42(5). 260–263. 4 indexed citations
2.
Armstrong, Andrew J., Carl A. Olsson, Ian D. Schnadig, et al.. (2019). Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). 177–177.
3.
Gao, Mei, Richard A. Moffitt, Jinha Park, et al.. (2018). Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. British Journal of Cancer. 120(1). 88–96. 39 indexed citations
4.
Vacirca, Jeffrey, Arlene Chan, Zsuzsanna Pápai, et al.. (2018). An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer. Cancer Medicine. 7(5). 1660–1669. 10 indexed citations
5.
Porter, John B., Kris V. Kowdley, Alì Taher, et al.. (2018). Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults. Blood. 132(Supplement 1). 2336–2336. 8 indexed citations
6.
O’Shaughnessy, Joyce, Martine Piccart, Lee S. Schwartzberg, et al.. (2018). Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).. Journal of Clinical Oncology. 36(15_suppl). TPS1106–TPS1106. 2 indexed citations
7.
8.
Chen, Robert W., Stephen M. Ansell, Pier Luigi Zinzani, et al.. (2017). Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. Journal of Clinical Oncology. 35(15_suppl). TPS7575–TPS7575. 3 indexed citations
9.
Picozzi, Vincent J., S Narayanan, Xiucai Hu, & Jeffrey Vacirca. (2016). Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer. Journal of Gastrointestinal Cancer. 48(1). 103–109. 20 indexed citations
10.
11.
Schnadig, Ian D., Richy Agajanian, Christopher Dakhil, et al.. (2016). APF530 (Granisetron Injection Extended-Release) in a Three-Drug Regimen for Delayed CINV in Highly Emetogenic Chemotherapy. Future Oncology. 12(12). 1469–1481. 17 indexed citations
12.
Wang, Kai, Adrienne Johnson, Siraj M. Ali, et al.. (2015). Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. The Oncologist. 20(10). 1132–1139. 75 indexed citations
13.
Vogelzang, Nicholas J., Jeffrey Vacirca, Philip W. Kantoff, et al.. (2014). Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts).. Journal of Clinical Oncology. 32(4_suppl). 185–185. 1 indexed citations
14.
Vacirca, Jeffrey, et al.. (2013). Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Annals of Hematology. 93(3). 403–409. 72 indexed citations
15.
Vacirca, Jeffrey, et al.. (2013). The 340b drug discount program: oncology's optical illusion.. PubMed. 27(11). 1068, 1070, 1072–1068, 1070, 1072. 3 indexed citations
16.
Lee, Christopher C., et al.. (2010). Reversible posterior leukoencephalopathy syndrome after rituximab. The American Journal of Emergency Medicine. 28(4). 537.e1–537.e2. 11 indexed citations
17.
Vacirca, Jeffrey, et al.. (2010). Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology. 28(15_suppl). 8041–8041. 3 indexed citations
18.
Vacirca, Jeffrey. (2009). Bendamustine Combined with Rituximab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.. Blood. 114(22). 4750–4750. 3 indexed citations
19.
Rosenfeldt, Mathias T., Michael Valentino, L E Scudder, et al.. (2005). The organomercurial 4-aminophenylmercuric acetate, independent of matrix metalloproteinases, induces dose-dependent activation/ inhibition of platelet aggregation. Thrombosis and Haemostasis. 93(2). 326–330. 5 indexed citations
20.
Zucker, Stanley & Jeffrey Vacirca. (2003). Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer and Metastasis Reviews. 23(1-2). 101–117. 432 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chun‐Chieh Wu Breakdown of academic impact, for papers by Philipp Manegold Breakdown of academic impact, for papers by Tingting Zhao Breakdown of academic impact, for papers by Véronique Neaud Breakdown of academic impact, for papers by Berno Tanner Breakdown of academic impact, for papers by Yifu He Breakdown of academic impact, for papers by Nigel C. Bird Breakdown of academic impact, for papers by Carolina Bizama Breakdown of academic impact, for papers by Hye Kyung Hong
Rankless by CCL
2026